Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies - Obligations for Each Relevant Transaction (Details)

v3.22.2
Summary of Significant Accounting Policies - Obligations for Each Relevant Transaction (Details)
$ in Thousands
Dec. 31, 2021
USD ($)
Bayon acquisition | Successful completion of Phase 1b $0.495 million  
Business Acquisition [Line Items]  
Fair value of contingent consideration $ 495
Bayon acquisition | Successful completion of Phase 2 $0.990 million  
Business Acquisition [Line Items]  
Fair value of contingent consideration 990
Bayon acquisition | Successful completion of Phase 3 $4 million  
Business Acquisition [Line Items]  
Fair value of contingent consideration 4,000
Bayon acquisition | FDA approval  
Business Acquisition [Line Items]  
Fair value of contingent consideration 1,650
Panoptes acquisition | Beginning of Phase 3  
Business Acquisition [Line Items]  
Fair value of contingent consideration 4,750
Panoptes acquisition | FDA approval  
Business Acquisition [Line Items]  
Fair value of contingent consideration 4,750
Jade acquisition | FDA approval  
Business Acquisition [Line Items]  
Fair value of contingent consideration $ 2,164